Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

The ACA and the Future of the BPCIA (<i>The Center for Biosimilars</i>)

main

08_09 Press Post_The ACA and the Future of BPCIA

Press Post: The ACA and the Future of the BPCIA (The Center for Biosimilars)

The ACA and the Future of the BPCIA (The Center for Biosimilars)

Related Content

FDA Approves BLA for Novavax’s COVID-19 Vaccine

Biogen Files Suit Against Neurimmune Over Rights to Bispecific Antibody

HyClone Seeks to Quash Amgen’s Subpoena Issued in Amgen/Accord Denosumab BPCIA Litigation

Regeneron Awarded $407 Million in Amgen Antitrust Suit

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with STELARA (ustekinumab)

Join Us! The Future of Biotech Regulation Webinar

Third Circuit Affirms Rejection of AstraZeneca’s Challenges to IRA Drug Price Negotiation Program

President Trump Issues Two Executive Orders Concerning the Affordability and Accessibility of Drugs

Goodwin Guides Orionis Biosciences in Strategic Partnership with Genentech That Could Exceed $2 Billion to Discover and Develop Molecular Glue Class Medicines for Cancer

Goodwin is Number One Law Firm in League Table Rankings for Q1 2025

Goodwin Named to Los Angeles Business Journal’s 2025 List of Largest Law Firms in LA

Vigil Neuroscience To Be Acquired by Sanofi For 470 Million and Contingent Value Rights

Goodwin Represents Inozyme Pharma in $270 Million Acquisition by BioMarin to Strengthen Enzyme Therapy Business

Goodwin Scales Life Sciences Practice in Boston with the Arrival of Partner Felipe Heiderich

Rare Disease Industry Awaits FDA Chief’s New Drug Pathway Plan (Bloomberg Law)

AI in Healthcare: Private Equity’s Next Frontier? (Real Deals)

Life Sciences

Life Sciences Patent Prosecution & Counseling

Patent Litigation

Patent Prosecution & Counseling

Patent Trial & Appeal Board

Hatch-Waxman, Biologics and Biosimilars Litigation